ClinicalTrials.gg
CompletedNCT03241108Updated Aug 14, 2018

Study of an Anti-TLR4 mAb in Rheumatoid Arthritis

A Phase 2 interventional study of NI-0101 and Placebo in Rheumatoid Arthritis, sponsored by Light Chain Bioscience - Novimmune SA. Completed at 19 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-08-14.

Sponsored by Light Chain Bioscience - Novimmune SA · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
90
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 34 studies in Arthritis, Rheumatoid with a site in Georgia — 6 open to participants now, 10 under way, none of them phase 3. Arthritis, Rheumatoid · Georgia.

Enrollment
23rd of 34
90 · median 135
Started
2017
with 1 other
Phase 2
21 of 34
1 open now
Registered
14th of 34
by date

Among the 34 studies in Arthritis, Rheumatoid with a site in Georgia, this one is the 23rd largest by enrollment, is one of 2 that started in 2017, is one of 21 in phase 2, and was the 14th registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 444 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

6 of the 34 studies in Arthritis, Rheumatoid with a site in Georgia are open now. Recruiting first, the newest first:

1 more — sign in →

All 6 open studies →

A study can be open while its sites in Georgia have not opened yet or have stopped. Only those recruiting at a site in Georgia →

Who these studies take

Of the 293 Arthritis, Rheumatoid studies recruiting now, 150 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 34 studies in Arthritis, Rheumatoid with a site in Georgia, or all of them as a file.
02

Study summary

This is a Phase 2, PoC, randomized, placebo-controlled, double blind, international multicentre study to explore the effect of a new antibody to treat patients with Rheumatoid Arthritis

Read the detailed description

The study foresees the randomization of at least 81 moderate to severe, ACPA positive, RA patients who are inadequate responders to MTX, in two double blind arms (NI-0101:placebo, with a ratio of 2:1). Patients will receive NI-0101 or placebo infusions up to a maximum of 6 administrations (every two weeks for 12 weeks). All patients will continue receiving a stable dose of MTX. After 12 weeks, patients will enter the follow up period with monthly visits for a minimum of 12 weeks.

03

Conditions studied

  • Rheumatoid Arthritis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female patients
  • Age >= 18 years old
  • : \< 30 and > 18
  • Diagnosis of RA according to 2010 ACR/EULAR criteria and with a disease duration of at least 6 months since diagnosis
  • Patient must present with active RA, characterized by at least 6 swollen joints out of 66 assessed and 6 tender joints out of 68 assessed and by the presence of synovitis (measured by ultrasound) in at least one of the 6 swollen joints
  • C-reactive protein (CRP) level > 0.7 mg/dL or if the CRP level is between 0.3 mg/dL and 0.7 mg/dL (included) then patient must also present an ESR > 30mm/hr
  • Patients must have received MTX treatment for at least 3 months and have been on a stable dose of MTX for at least 6 weeks prior to start of screening
  • ACPA-positive RA patients
  • Women must be (> 12 months without menses) or surgically sterile or using two effective methods for at least 4 weeks prior to the randomization date and agree to continue contraception for the duration of their participation in the study (until the end of follow up period)
  • Sexually active male patients must use a barrier method of contraception during the course of the study (and until the end of the follow up period)
  • Patients must give written for study participation

Exclusion criteria

Exclusion Criteria:

  • A documented history of an disease other than RA by ACR classification, or Sjögren syndrome
  • Administration of cytotoxic drugs and immune suppressants (other than MTX) within 3 months prior to screening
  • Previous multiple administrations of any biological DMARD or targeted synthetic DMARD
  • Known primary immunodeficiency
  • Pregnant or breastfeeding women
  • Suspicion of active or latent tuberculosis
  • , , infection
  • Infection reported during screening not recovered 72h prior to first dose
  • History of anaphylactic reactions to any protein therapeutics or
  • Any history of , excluding cured basal or squamous cell carcinoma of the skin, or cervical in situ carcinoma
  • cardiac disease requiring medication, such as congestive heart failure, unstable angina, myocardial infarction within 6 months prior to randomization
  • Moderate to severe renal insufficiency, clinically relevant liver function test abnormalities or pancytopenia
  • Major psychiatric or neurological disorder
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
90 participants (actual)

Study arms

  • Experimental
    NI-0101

    A therapeutic humanized monoclonal antibody, administered by intravenous infusion every 2 weeks.

    Drug: NI-0101

  • Placebo comparator
    Placebo

    The placebo matches NI-0101 without active ingredient, administered by intravenous infusion every 2 weeks.

    Other: Placebo

Interventions

  • Humanized immunoglobulin gamma 1 (IgG1) kappa monoclonal antibody targeting TLR4

  • OtherPlacebo

    Placebo

06

What researchers measure

Primary outcomes

  1. Incidence, severity, causality and outcomes of Adverse Events (AEs)

    Incidence, severity, causality and outcomes of Adverse Events (AEs) (serious and non-serious), with particular attention being paid to infusion-related reactions and infections

    Time frame: From screening up to 24 weeks after first treatment administration

  2. Withdrawal for safety reasons

    Time frame: From randomization up to 24 weeks after first treatment administration

  3. Evolution of laboratory parameters

    Time frame: From screening up to 24 weeks after first treatment administration

  4. Level of potential circulating antibodies against NI-0101

    Level of potential circulating antibodies against NI-0101 to determine immunogenicity; i.e. the development of anti-drug antibodies (ADA).

    Time frame: From screening up to 24 weeks after first treatment administration

  5. Levels of CRP

    Levels of C-Reactive protein (CRP)

    Time frame: From screening up to 24 weeks after first treatment administration

  6. Levels of inflammatory cytokines/chemokines

    IL-6, TNFa, IP-10, MCP-1, sICAM, CXCL13

    Time frame: From screening up to 24 weeks after first treatment administration

  7. DAS28 CRP

    Measure of Disease Activity Scores (DAS) for Rheumatism in 28 tender or swollen joints and C-Reactive protein (CRP) - DAS28-CRP

    Time frame: From screening to 24 weeks after first treatment administration

  8. ACR criteria

    Proportion of patients achieving American College of Rheumatology Criteria (ACR20, ACR50 and ACR70)

    Time frame: From randomization to 24 weeks after first treatment administration

  9. Proportion of patient achieving remission

    Proportion of patient achieving remission (defined as DAS28 \< 2.6)

    Time frame: From randomization to 24 weeks after first treatment administration

  10. EULAR response

    Proportion of patients achieving European League Against Rheumatism (EULAR) response criteria - good, moderate and no response

    Time frame: From randomization to 24 weeks after first treatment administration

  11. Joint Count

    Mean number of Tender Joint Count/Swollen Joint Count.

    Time frame: From screening to 24 weeks after first treatment administration

  12. SDAI score

    Mean improvement from baseline in Simplified Disease Activity Index (SDAI) score

    Time frame: From randomization to 24 weeks after first treatment administration

  13. HAQ-DI score

    Mean improvement from baseline in the Health Assessment Questionnaire without Disability Index (HAQ-DI) score

    Time frame: From randomization to 24 weeks after first treatment administration

  14. SF-36 score

    Mean improvement from baseline in 36-Item Short-Form Health Survey (SF-36) score

    Time frame: from randomization to 24 weeks after first treatment administration

  15. DAS28-ESR

    Measure of Disease Activity Scores (DAS) for Rheumatism in 28 tender or swollen joints and Erythrocyte Sedimentation Rate (ESR) levels - DAS28-ESR

    Time frame: From screening to 24 weeks after first treatment administration

  16. CDAI score

    Mean improvement from baseline in Clinical Disease Activity Index (CDAI) score scores

    Time frame: From randomization to 24 weeks after first treatment administration

  17. Exploratory PK analysis - Cmax

    Peak drug plasma concentration (Cmax)

    Time frame: From randomization to 24 weeks after first treatment administration

  18. Exploratory PK analysis - Tmax

    Time when plasma concentration is at peak (Tmax)

    Time frame: From screening up to 24 weeks after first treatment administration

  19. Exploratory PK analysis - Ctrough

    Plasma drug concentration immediately prior next dosing (Ctrough)

    Time frame: From randomization to 24 weeks after first treatment administration

  20. Exploratory PK analysis - AUC

    Area under the plasma concentration versus time curve (AUC)

    Time frame: From randomization to 24 weeks after first treatment administration

  21. Exploratory PK analysis - CL

    Systemic drug clearance (CL)

    Time frame: From randomization to 24 weeks after first treatment administration

07

Study locations

19 sites
  • Clinic for internal medicine with centre for dialysis
    Mostar, 88000, Bosnia and Herzegovina
  • Multi-profile Hospital for Active Treatment "Trimontsium"
    Plovdiv, 4000, Bulgaria
  • University Multiprofile Hospital for Active Treatment "Kaspela"
    Plovdiv, 4001, Bulgaria
  • Multiprofile Hospital for Active Treatment - Shumen AD
    Shumen, 9705, Bulgaria
  • University Multiprofile Hospital for Active TreatmenT "St. Ivan Rilski"
    Sofia, 1612, Bulgaria
  • ARENSIA Phase I Unit at the Research Institute of Clinical Medicine
    Tbilisi, 0112, Georgia
  • High Technology Medical Center; University clinic
    Tbilisi, 0144, Georgia
  • Emergency Cardiology Center by Acad. G.Chapidze
    Tbilisi, 0159, Georgia
  • Insitute of Clinical Cardiology
    Tbilisi, 0159, Georgia
  • Tbilisi Central Hospital
    Tbilisi, 0159, Georgia
  • Multiprofile Clinic Consilium Medulla
    Tbilisi, 0186, Georgia
  • CRU Hungary Ltd
    Miskolc, 3529, Hungary
  • Republican Clinical Hospital, ARENSIA Phase I unit
    Chisinau, MD2025, Moldova, Republic of
  • Centrum Miriada
    Bialystok, 15-297, Poland
  • Zespól Poradni Specjalistycznych REUMED
    Lublin, 20-582, Poland
  • Institute of Rheumatology
    Belgrade, 11000, Serbia
  • Clinical Center Kragujevac
    Kragujevac, 34000, Serbia
  • Special Hospital for Rheumatic Diseases "Novi Sad"
    Novi Sad, 21112, Serbia
  • General Hospital "Djordje Joanovic"
    Zrenjanin, 23000, Serbia
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2017 to primary completion in Jun 2018, 13 months.

Of 116 industry-sponsored phase 2 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 24. This study's 13 months is below that.

Counting every sponsor, half of 158 studies reached it within 18 months; a quarter within 13 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 26, 2017
First posted
Aug 7, 2017
StartActual
May 10, 2017
Primary completionActual
Jun 20, 2018
CompletionActual
Jun 20, 2018
Last update
Aug 14, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 14, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03241108
Lead sponsor
Light Chain Bioscience - Novimmune SA
Responsible party
Sponsor
First posted
Aug 7, 2017
Start date
May 10, 2017
Primary completion
Jun 20, 2018
Completion
Jun 20, 2018
Last update
Aug 14, 2018

Study contacts

Ernest Choy, MD
principal investigator · Institute of Infection and Immunity, Cardiff University School of Medicine

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: NI-0101

Start the discussion